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OBJECTIVE — Continuous -cell rest with diazoxide preserves residual endogenous insulin
production in type 1 diabetes. However, side effects have hampered therapeutic usefulness. In a
double-blind study, we tested whether lower, intermittent dosing of diazoxide had beneﬁcial
effects on insulin production, metabolic control, and autoimmunity markers in the absence of
side effects.
RESEARCH DESIGN AND METHODS — Forty-one newly diagnosed type 1 diabetic
patients were randomized to 6 months of treatment with placebo or 100 mg diazoxide at
bedtime. A1C, C-peptide (fasting and glucagon stimulated), and FoxP3
 regulatory T-cells
(Tregs) were measured. Patients were followed for 6 months after intervention.
RESULTS — Of six dropouts, three were due to perceived side effects; one subject in the
diazoxide group experienced rash, another dizziness, and one in the placebo group sleep dis-
turbance. Adverse effects in others were absent. Diazoxide treatment reduced A1C from 8.6% at
baseline to 6.0% at 6 months and 6.5% at 12 months. Corresponding A1C value in the placebo
arm were 8.3, 7.3, and 7.5% (P  0.05 for stronger reduction in the diazoxide group). Fasting
and stimulated C-peptide decreased during 12 months similarly in both arms (mean 0.30 and
0.18 nmol/l in the diazoxide arm and 0.08 and 0.09 nmol/l in the placebo arm). The
proportion of Tregs was similar in both arms and remained stable during intervention but was
signiﬁcantly lower compared with nondiabetic subjects.
CONCLUSIONS — Six months of low-dose diazoxide was without side effects and did not
measurably affect insulin production but was associated with improved metabolic control.
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reservation of residual insulin pro-
ductionintype1diabeticpatientsis
accompaniedbyimprovedglycemic
control, reduced microvascular compli-
cations, and reduced number of hypogly-
cemic events (1,2). To retain residual
insulin secretion is thus highly desirable.
Autoimmune mechanisms are of
main importance for -cell destruction in
type 1 diabetes. Accordingly, immuno-
suppressive treatment retards the de-
structive process (3–5) and thus has
therapeutic potential. But also, the degree
of metabolic control affects, whether by
modulation of autoimmune activity or by
other mechanisms, the rate of -cell dete-
rioration. Thus, in the Diabetes Control
and Complications Trial (DCCT), inten-
sive insulin treatment, which achieved
lower A1C than conventional treatment,
also markedly retarded deterioration in
C-peptide levels (2). This favorable effect
could be due to lesser hyperglycemia, per
se, but also to a lesser degree of over-
stimulation of the -cells (i.e., “-cell
rest”).
Diazoxide provides -cell rest by re-
versibly suppressing glucose-induced in-
sulin secretion through opening ATP-
sensitive K
 channels in the -cell (6). A
beneﬁcial effect of 3 months treatment
with diazoxide was documented in 20
newly diagnosed type 1 diabetic subjects.
Diazoxide (4–6 kg   kg
1   24 h
1, i.e.,
280–420 mg for a 70-kg subject) or pla-
cebo was divided into capsules taken
three times daily (7). After the interven-
tion, C-peptide levels were better pre-
served in diazoxide- versus placebo-
treated subjects for up to 18 months.
Ortqvist et al. (8) obtained similar results
with diazoxide 5–7.5 mg   kg
1   day
1
given to pediatric patients for 3 months.
However, disturbing side effects (lanugo
hair growth, edema, and hypotension)
werefrequentandhavehamperedfurther
studies with diazoxide (7,8).
No studies have tested whether a
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nate side effects and still exert a beneﬁcial
effect on insulin production and meta-
bolic control in type 1 diabetes. We re-
cently treated type 2 diabetic subjects
using a reduced, intermittent dosing of
diazoxide (i.e., 100 mg at bedtime)
(9,10). Side effects were then absent and
insulin production improved provided
that patients were simultaneously treated
with bedtime insulin (9). These results
encouraged us to perform a similar study
in type 1 diabetes.
Beneﬁcial effects of diazoxide in pre-
vious type 1 diabetes studies have been
proposed to be due to -cell rest and di-
minishing cellular autoimmune activity
(11,12). However, studies on the effects
on T-cell subpopulations are lacking.
Among these, much recent evidence
points to the importance of regulatory T-
cells (Tregs) (13). Tregs were originally
characterized by strong expression of in-
terleukin (IL)-2R, CD25, and recently
andmorespeciﬁcallybyexpressionofthe
transcription factor forkhead box P3
(FoxP3) (14,15). It was therefore of inter-
estinourtrialtolookforarelativechange
in Treg populations.
The aims of this study were thus to
investigate in newly diagnosed subjects
with type 1 diabetes whether a low-dose
and intermittent treatment with diazox-
ide would 1) be devoid of side effects; 2)
lead to better endogenous insulin secre-
tion, measured by fasting and stimulated
C-peptide; 3) have beneﬁcial effects on
metabolic control, measured by A1C and
home glucose monitoring; and 4) affect
autoimmune processes, measured by glu-
tamic acid decarboxylase (GAD)-65 and
islet antigen (IA)-2 antibody titers and by
the FoxP3 marker of regulatory T-cells.
RESEARCH DESIGN AND
METHODS— Patients were recruited
between February 2005 and June 2007
from the university hospitals of St. Olav,
Akershus, Stavanger, Haukeland, and
North Norway as well as Levanger Hospi-
tal. Inclusion criteria were age 18–40
years, insulin-dependent diabetes with
positive test for GADA and/or IA-2A (an-
tibodiesagainstGAD65andIA-2),fasting
C-peptide level 0.2 nmol/l, and diabe-
tes duration 12 weeks. Exclusion crite-
ria were evidence of drug and alcohol
abuse. Further, we did not include
women who were pregnant or who did
not use contraception. Patients were
given oral and written information before
consenting to participate. The study pro-
tocol was approved by the regional ethics
committee and the Norwegian Drug
Agency. Details of study design can be
found in the online appendix (supple-
mental Table 1 in the online appendix
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1436/DC1]).
Before inclusion, all patients under-
went a clinical examination and blood
sampling for assessment of blood count,
lipid proﬁle, and renal and liver function.
All patients received a standard multi-
injection regimen consisting of mealtime
monomericshort-actinginsulinandlong-
actingNPHinsulintwicedaily(exceptfor
two subjects in the diazoxide group and
three in the placebo group who received
NPH insulin only at night). After obtain-
ing fasting blood glucose consistently be-
tween 4 and 6 mmol/l and postprandial
levels between 5 and 7 mmol/l, the pa-
tientsweredouble-blindlyrandomizedto
either 100 mg diazoxide at night or pla-
cebo. Randomization was stratiﬁed for
age 25 or 25 years. The intervention
lasted 6 months and the follow-up period
another6months.Theprimaryendpoint
was -cell function, assessed by fasting
and glucagon-stimulated C-peptide. Sec-
ondary end points were glycemic control
(A1C and blood glucose), insulin dosage,
and markers of autoimmunity (GADA,
IA-2A, and Tregs).
The study visits took place at baseline
and once every 3 months. Visits were fo-
cused on glycemic control and occur-
rence of side effects. Each visit included a
clinical investigation and measurements
of fasting blood glucose, blood pressure,
and body weight. Patients were also
examined for presence of edema and
askedabouttheoccurrenceofhypoglyce-
mia and adverse events. Hypoglycemic
episodes were registered as minor or ma-
jor events depending on coping or not.
We registered current insulin dosage
(fast- and long-acting) at each visit.
C-peptide glucagon stimulation tests
were performed in duplicate at baseline
andevery3monthsthereafter.Intotal,10
tests were performed in each participant.
Blood was sampled in the overnight-
fasted state and 6 min after the intrave-
nous injection of 1 mg glucagon.
Patients were to perform seven-point
home glucose monitoring (7pHGM) dur-
ing 3 consecutive days at baseline, during
intervention, and between 3 and 6
months after intervention. Blood glucose
was measured fasting, 2 h after breakfast,
before lunch, 2 h after lunch, before din-
ner, 2 h after dinner, and at bedtime us-
ing the patients’ own blood glucose–
measuring device.
Diazoxide was provided by TEVA
Pharmaceuticals Europe (Utrecht, the
Netherlands). Manufacture of drug and
placebo capsules was performed by the
KragerøTabletProductionUnit(Kragerø,
Norway). At baseline and at the end of
intervention, we isolated peripheral
blood mononuclear cells (PBMCs) from
11subjectsinthediazoxide-treatedand9
subjects in the placebo-treated group.
Cells were isolated by separation on Lym-
phoprep(Axis-Shield,Oslo,Norway)and
then stored below 140°C. We also iso-
lated PBMCs from 20 nondiabetic, age-
and sex-matched blood donors. After
thawing,thecellswereprocessedthrough
a FACSCanato ﬂow cytometer (BD Bio-
sciences,SanJose,CA).Fordetailsseethe
online appendix.
Assays
A1C was assayed by a DCA 2000 (Bayer
ASDiagnostics,Oslo,Norway).Reference
levels deﬁning normality were between
3.0 and 6.0%. C-peptide, insulin, glu-
cagon, and proinsulin were assayed by
radioimmunoassay (Linco Research, St.
Louis, MO). GADAs and IA-2As were
determined by enzyme-linked immu-
nosorbent assay (Medizym; Medipan
Diagnostica, Selchow, Germany). Titers
of GADA 5 units and of IA-2A 10
units were regarded as positive.
Statistics
The coefﬁcient of variation (CV) for fast-
ing C-peptide is 13% (16). To detect a
20% difference with 80% certainty, one
would only need eight patients in each
group. Considering a spontaneous varia-
tion in C-peptide decline, we planned to
include 50% more patients. Assuming a
10% dropout, 36 patients would then
need to be included.
For C-peptide glucagon tests, we
used the mean values of duplicates for
analyses. For 7pHGM, we used the me-
dianbecauseofhighspreadinsomeofthe
values. All other results are given as
meansSE.Signiﬁcancetestingwasper-
formed using the Mann-Whitney test. Di-
chotomous variables were analyzed using
thePearsons
2test.Toassessinsulinsen-
sitivity, weused the homeostasis model as-
sessment (HOMA) calculator from Oxford
university (http://www.dtu.ox.ac.uk).
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Dropouts
Forty-one patients were randomized to
either diazoxide (no. 22) or placebo (no.
19).Sixpatientswereexcludedduringin-
tervention, all of these during the ﬁrst 3
months of intervention. Three patients
dropped out for personal reasons (one
from the diazoxide group and two from
the placebo group). Three patients were
excluded due to assumed side effects
(from the diazoxide group, one due to a
rash and another due to dizziness). In the
placebo group, one patient experienced
sleepdisturbances,whichdisappearedaf-
ter drug cessation. Compared with com-
pleters, the dropouts were slightly older,
more overweight, had higher blood pres-
sure, and had higher fasting C-peptide at
baselinebutcomparableglycemiccontrol
(Table 1). The remaining 35 patients
completed the study. A random third was
asked to return the unused capsules after
intervention.Theamountofunusedmed-
ication agreed with the prescribed doses
of the study medication.
Baseline characteristics
Age and sex distribution did not differ be-
tween groups. Ketoacidosis at ﬁrst referral
was registered in three patients in each
group. The diazoxide group had signiﬁ-
cantlyshorterdiseasedurationbeforeinclu-
sion versus the placebo group. There was a
signiﬁcant decrease in C-peptide levels of
0.17  0.04 (P  0.003) in subjects as a
whole from the time of diagnosis to
inclusion.
Clinical examination and routine
blood testing (see RESEARCH DESIGN AND
METHODS) were normal (data not shown).
Blood pressure, BMI, glycemic control,
and fasting C-peptide levels did not differ
between the groups. The use of nicotine
was equally distributed. In the diazoxide
group, two patients used oral contracep-
tives, one used a statin, one used a proton
pump inhibitor, and one used gabapen-
tin. In the placebo group, three patients
used oral contraceptives and one was on
asthma inhalation therapy containing
glucocorticoids (Table 1).
Body weight
The diazoxide group gained 1.1  0.75 kg
in total during the study period. The pla-
cebo group gained 1.8  1.0 kg during the
ﬁrst3monthsandhadatotalweightgainof
2.0  1.5 kg. This was signiﬁcantly higher
than in the diazoxide group (P  0.040).
Insulin dosage
There was no signiﬁcant difference in in-
sulin dosage (total and long acting) be-
tween groups (supplemental Table 2).
Glycemic control
A1C improved in the diazoxide-treated
group compared with the placebo group
both during intervention and during fol-
low-up(Fig.1).Neitherfastingbloodglu-
cose at the study visits nor the 7pHGM
registration showed signiﬁcant changes
during intervention. However, 3 months
after intervention, the fasting blood glu-
cose decreased signiﬁcantly, by 1.4
mmol/l in the diazoxide-treated group,
whileincreasingby1.1mmol/linthepla-
cebo group (P  0.017 for difference be-
tween groups). The same tendency was
seen 6 months after intervention. Only
51% of the patients completed the
7pHGM registrations after the interven-
tion. By these data, there was a tendency
(P  0.158) for a reduction in blood glu-
cose before and after breakfast in the dia-
zoxide-treated versus placebo group.
Hypoglycemic events
The self-reported frequency of hypogly-
cemiceventsbeforeinclusionwascompa-
rable between the two groups. During
intervention, ﬁve patients in the diazox-
ide group reported frequent minor hypo-
glycemic events (10 events during 6
months). Five patients in the placebo
group reported frequently minor hypo-
glycemia and two reported one major
event each.
Parameters of -cell function
Fasting and glucagon-stimulated C-
peptide levels decreased similarly in both
groups throughout the study. From com-
parable baseline values, the fasting C-
peptide in the diazoxide group decreased
by 0.05  0.03 nmol/l after intervention
and by 0.13  0.02 nmol/l after 12
months. The decrement in the placebo
group was 0.02  0.05 and 0.08  0.04,
respectively (supplemental Table 3).
Stimulated C-peptide levels showed the
same pattern; from a baseline value of
0.53  0.07 nmol/l, the decrement was
0.1  0.04 and 0.18  0.04 in the dia-
zoxide group. In the placebo group, the
baseline value was 0.6  0.1 nmol/l and
decreased by 0.04  0.07 and 0.09 
0.07, respectively.
To adjust for different glucose con-
centrations, we calculated the ratio of C-
peptide to glucose (Fig. 2). No signiﬁcant
difference between groups was observed.
Also fasting levels of insulin, proinsulin,
and glucagon did not change during the
study (supplemental Table 3).
Insulin sensitivity
Insulin sensitivity as assessed by HOMA-S%
was comparable between the groups at
baseline. After 3, 9, and 12 months, the
HOMA-S% increased by, respectively,
16, 14, and 32% in the diazoxide group.
Sensitivity remained stable in the placebo
group (3, 0, and 4% for the same time
periods, P  0.020, 0.147, and 0.072,
respectively, for differences between the
groups).
Measurements of GADA and IA-2A
All patients were by selection criteria posi-
tive for GADA. Twenty-four subjects were
additionally positive for IA-2A. Divided by
groupadherence,74%inthediazoxideand
63% of subjects in the placebo group were
positiveforbothantibodies.TitersofGADA
and IA-2A before intervention were similar
between groups. Participants taken to-
getherhadameanGADAtiteratthestartof
182  15 and 168  15 units after 12
Table 1—Baseline characteristics
Diazoxide Placebo Dropouts
Age (years) 27.5  1.60 27.0  1.76 30.8  1.64
Sex (male/female) 13/6 12/4 4/2
BMI (kg/m²) 24.8  0.78 26.0  1.38 27.2  3.53
Systolic blood pressure (mmHg) 122  2.7 116  3.6 126  5.1
Diastolic blood pressure (mmHg) 75  2.1 72  1.9 79  3.8
Time of inclusion after diagnosis of
diabetes (weeks) 5.0  1 8.0  2 7.6  1
Nicotine use (yes/no) 6/13 6/10 2/4
Fasting glucose (mmol/l) 7.5  0.59 7.9  0.46 7.8  1.50
A1C (%) 8.6  0.38 8.3  0.56 8.1  0.90
C-peptide (nmol/l) 0.31  0.03 0.34  0.05 0.56  0.08
Data are means  SE.
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niﬁcantly smaller in the diazoxide-treated
group (P  0.133). The mean IA-2A (all
participants)was18830unitsatbaseline
and 168  31 units after 12 months.
Subjects who were positive for both
GADA and IA-2A had a tendency for a
more pronounced decline in fasting
C-peptide after 6 (P  0.092) and 12
months (P  0.128) compared with
subjects who were only GADA positive,
with a similar aggravating effect on
stimulated C-peptide after 12 months
(P  0.083).
PMBCs and Tregs
The proportion of CD4
 lymphocytes to
the total number of lymphocytes did not
differbetweenthediabeticgroupsandthe
healthy control group (supplemental Fig.
1). The proportion of rTregs and aTregs,
expressed, respectively, as the proportion
of CD4
/CD45RA
/CD25
/FoxP3

cells to the total number of CD4
/
CD45RA
 cells and the proportion of
CD4
/CD45RA
/CD25
/FoxP3
 to the
total number of CD4
/CD45RA
 cells,
did not differ between the diazoxide-
and placebo-treated groups (supple-
mental Figs. 2 and 3). The results were
the same when the groups were split
into C-peptide decline over or below
the median (supplemental Fig. 4). Like-
wise, when Tregs were compared in
high versus low titers of GADA and
IA-2A or numbers of antibodies (i.e.,
one or two antibodies), there was no
detectable correlation of the Treg ratio
to disease activity (data not shown).
However, we found evidence for a small
overall downregulation of Tregs in the
diabetic group versus the nondiabetic
group. This signiﬁcant difference was
foundbothfortherTregsandtheaTregs
(supplemental Figs. 2–4).
Figure1—ChangesinA1Cfrombaseline,recordedafter3,6,9,and12monthsofthestudy(meansSE).Baselinemeanvaluesfordiazoxide:8.6%;
for placebo: 8.3%. f, diazoxide-treated subjects;  , placebo-treated subjects.
Figure 2—Fasting and stimulated values of C-peptide–to–glucose ratio at 0, 3, 6, 9, and 12
months. F, diazoxide-treated subjects; E, placebo-treated subjects.
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longest intervention trial with diazoxide
so far performed in subjects with diabe-
tes. The main ﬁndings are that 6 months
of low-dose diazoxide treatment was ac-
companied with few side effects and did
not measurably affect residual insulin
production but was associated with im-
proved metabolic control.
Theabsence(ornearabsence)ofwell-
knownsideeffects(7,8)isinlinewithour
previous studies in type 2 diabetic pa-
tients(9,10).Thisstudyextendstheseob-
servations to a younger age-group and a
longer treatment period. A low drop-out
rate attests to acceptability of treatment.
Compliance with the intervention was
further corroborated by satisfactory re-
sults from capsule counting. One may
conclude that further long-term studies
with low-dosage diazoxide, if they are in-
deed indicated, is not hampered by con-
cerns about safety or compliance.
In contrast to the previous studies
(7,8), we did not observe any postinter-
vention effect on fasting or glucagon-
stimulated levels of C-peptide. The study
of Bjo ¨rk et al. (7), which reported beneﬁ-
cial effects of diazoxide treatment, is the
studymostsimilartoours;adiscussionof
differencesofpotentialimportanceisthus
inorder.Age,C-peptidelevelsatbaseline,
and method of testing insulin production
were similar. Participants in the Bjo ¨rket
al. study were included within a week af-
ter diagnosis, while intervention in our
subjects started up to 12 weeks after ini-
tiation of insulin treatment (in line with
current recommendations [17]). It seems
possible that our subjects were in partial
remission at baseline, whereas the partic-
ipants in the Bjo ¨rk et al. study had at that
time not entered remission. The implica-
tions of such a difference are however not
clear.
A simple explanation for the lack of
measurable effects on insulin production
might be the lower dosage of diazoxide.
We used a dose of diazoxide that was
about one-third of the dose used in the
Bjo ¨rk et al. study. We reasoned that a
longer intervention period (i.e., 6 rather
than 3 months in the previous studies)
could compensate for a lower dose. Such
a putative effect may, however, have been
nulliﬁed by a blunting of the effects of
diazoxide with time. Thus, there was at
least a tendency for inhibition of fasting
and stimulated C-peptide after 3 months
of intervention but no such effect at the
end of the 6-month intervention period.
Thenotionoftime-dependentbluntingof
effects is compatible with the Bjo ¨r ke ta l .
study, in which the suppression of C-
peptide during intervention was blunted
already at the end of the 3-month inter-
vention period. Bjo ¨rk et al. assumed
blunting to be due to a recovery of the
secretory capacity of the -cell. This ex-
planation cannot be ruled out but is less
likely in the light of the postintervention
data in our study.
A1C improved signiﬁcantly in the
diazoxide group compared with placebo.
This effect was seen already during inter-
vention but persisted during the follow-
up. The cause of improved glycemic
control is not clear. One possibility is im-
proved insulin production that was not
picked up by the present methods of test-
ing (i.e., fasting and glucagon-stimulated
C-peptide).Thefactthatthebeneﬁcialef-
fect lingered postintervention would be
compatible with a hidden postinterven-
tioneffectofdiazoxideon-cellfunction.
One cannot rule out that other tests of
-cell function, such as meal-stimulated
secretion, would have detected a differ-
ence. However, we have no evidence to
support this notion. An alternative or
additional possibility is that diazoxide
favorably affects metabolic control by
improving insulin sensitivity. Such a no-
tion is compatible with the insulin re-
quirement not being enhanced in the
diazoxide-treated group despite the ex-
pected inhibitory effect of diazoxide on
insulin secretion. Similar observations
were made in the two previous clinical
studies (7,8), and data from animal stud-
ies have indicated improved sensitivity
(18). Further, when we calculated
HOMA-S%(rarelydoneintype1diabetes
but deemed admissible [19]), there was
signiﬁcantimprovementinthediazoxide-
treated group during the intervention.
The molecular mechanisms for an
insulin-sensitizing effect of diazoxide
remain to be clariﬁed. Of possible sig-
niﬁcance is the fact that body weight in-
creasedmoreintheplacebogroupduring
the ﬁrst 3 months. In animal studies, dia-
zoxidedecreasesappetite(20),andasim-
ilar, albeit unproven, effect could be
operative in humans (21).
To our knowledge, ours is the ﬁrst
studytoprospectivelyanalyzetherelative
Treg proportion in PBMCs during the
earlyphaseoftype1diabetes.TheFOXP3
marker was unaltered through the 6-
month intervention period both in the
diazoxide and the placebo group. On the
other hand, the Treg ratio differed signif-
icantlybetweenage-matchednondiabetic
subjects and the type 1 diabetic subjects.
These observations are in contrast to a
previous report (22), which, however,
did not focus speciﬁcally on differences
between newly diagnosed type 1 diabetes
versus healthy subjects. In our study, the
samples from the healthy control subjects
were assembled in one center (Trond-
heim), thus avoiding the transportation
necessary for many of the diabetes sam-
ples. However, we did not ﬁnd any differ-
ences between samples from Trondheim
and those from other centers (results not
shown). Nevertheless, the observed dif-
ferences between nondiabetic and dia-
betic subjects need to be conﬁrmed by an
independent study, ideally performed in
freshly isolated cells. As to humoral auto-
immunity,we,asothers(7,8),didnotde-
tectanysigniﬁcantinﬂuencebydiazoxide
on GADA levels.
Are further studies with diazoxide in
type 1 diabetes warranted? At ﬁrst glance,
the lack of effects on endogenous insulin
production would speak against such
endeavors. However, since diazoxide at
higher dosage does exert beneﬁcial
effects, a beneﬁcial effect on insulin
productionatthepresentdoseinacom-
bination therapy, for instance together
with an immunosuppressant, does not
seem unreasonable. In any case, the
beneﬁcial effects of diazoxide on meta-
bolic control that we observe could be
welcome in a combination therapy.
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